filgrastim

Pre-clinicalCompleted

0 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Normal PBPC Donors

Conditions

Normal PBPC Donors

Trial Timeline

Nov 1, 2003 → Sep 1, 2007

NCT ID

NCT00115128

About filgrastim

filgrastim is a pre-clinical stage product being developed by Amgen for Normal PBPC Donors. The current trial status is completed. This product is registered under clinical trial identifier NCT00115128. Target conditions include Normal PBPC Donors.

What happened to similar drugs?

4 of 6 similar drugs in Normal PBPC Donors were approved

Approved (4) Terminated (2) Active (2)

✅DonepezilEisaiApproved

✅Eybelis ophthalmic solution 0.002%Santen PharmaceuticalApproved

✅cyclosporine micro-emulsionNovartisApproved

✅Aspirin 100 mg + PlaceboBayerApproved

🔄Gadopentetate dimeglumine (Magnevist)BayerPhase 3

🔄lixivaptan + placeboBiogenPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00002126	Phase 2	Completed	—	—	HIV Infections
NCT00115128	Pre-clinical	Completed	Nov 1, 2003	Sep 1, 2007	Normal PBPC Donors
NCT00501228	Pre-clinical	Terminated	Feb 1, 2003	Sep 1, 2008	Graft-Versus-Host Disease

Competing Products

20 competing products in Normal PBPC Donors

See all competitors

Product	Company	Stage	Hype Score
Roxadustat	Astellas Pharma	Phase 1	29
Donepezil	Eisai	Approved	43
eribulin mesylate	Eisai	Phase 2	35
Lurasidone HCl	Sumitomo Pharma	Phase 1	29
Eybelis ophthalmic solution 0.002%	Santen Pharmaceutical	Approved	39
Triptorelin	Merck	Pre-clinical	26
Temozolomide + Vorinostat	Merck	Phase 2	35
LDE225	Novartis	Phase 1	29
LDK378	Novartis	Phase 1	29
cyclosporine micro-emulsion	Novartis	Approved	35
LDK378	Novartis	Phase 1	29
LEE011	Novartis	Phase 1	29
LEE011	Novartis	Phase 1	29
mycophenolate mofetil	Roche	Phase 1	29
PF-06423264	Pfizer	Phase 1	21
PF-05221304	Pfizer	Phase 1	29
BMS-933043 + Placebo matching with BMS-933043 + Antacid Buffer Predose Solution	Bristol Myers Squibb	Phase 1	29
tolebrutinib	Sanofi	Phase 1	29
Venglustat (GZ402671)	Sanofi	Phase 1	29
Rilzabrutinib	Sanofi	Phase 1	29